A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors
Condition(s):Solid Tumor, Adult; NSCLC; Urothelial Carcinoma; Gastric Cancer; Small Cell Lung Cancer; Hepatocellular Carcinoma; Cervical Carcinoma; Melanoma; Renal Cell Carcinoma; CarcinomaLast Updated:December 14, 2023Recruiting